Pentose, V.I. Technologies deal

VITX will evaluate the use of Pentose's Inactine antiviral technology as a second inactivation step that would include inactivation of non-enveloped viruses with VITX's marketed PLAS+SD virally inactivated transfusion plasma product. Pentose has received an upfront and a milestone payment from VITX. ...